WHO backs adding two Bundibugyo Ebola vaccine candidates to Congo trial

Situation Overview

On 4 November 2026, the World Health Organization (WHO) endorsed adding two new vaccine candidates to an ongoing clinical trial for a current Ebola outbreak caused by the Bundibugyo virus, for which no vaccine has been approved. WHO said the expert groups recommended including the two candidates developed specifically for Bundibugyo. The WHO Director-General, Tedros Adhanom Ghebreyesus, made the announcement during a press briefing in Geneva on 4 November. The two vaccine candidates are being developed by the University of Oxford, the Serum Institute of India and Moderna, and the trial is to be led by the National Institute for Bio (the article text is truncated). The outbreak has killed more than 5,300 people across multiple African countries, according to the report. The next concrete step described is the inclusion of the two Bundibugyo-specific vaccine candidates into the clinical trial following the WHO expert-group recommendation.

Geopolitical Implications

1. 01

   WHO’s decision underscores the need to adapt vaccines to specific Ebola variants, shaping international health-security coordination in Central Africa.

2. 02

   Trial expansion with major international developers highlights cross-border dependence on global biomedical capacity during outbreaks.

Key Signals

• —

  Inclusion of the two Bundibugyo vaccine candidates into the clinical trial following the WHO expert-group recommendation

Topics & Keywords

Market Impact Analysis

AI Threat Assessment

Event Timeline